These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

916 related articles for article (PubMed ID: 34492082)

  • 21. Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses.
    Ma X; Zou F; Yu F; Li R; Yuan Y; Zhang Y; Zhang X; Deng J; Chen T; Song Z; Qiao Y; Zhan Y; Liu J; Zhang J; Zhang X; Peng Z; Li Y; Lin Y; Liang L; Wang G; Chen Y; Chen Q; Pan T; He X; Zhang H
    Immunity; 2020 Dec; 53(6):1315-1330.e9. PubMed ID: 33275896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
    Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
    Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen.
    Srivastava V; Niu L; Phadke KS; Bellaire BH; Cho MW
    Front Immunol; 2021; 12():637982. PubMed ID: 33777030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung.
    Routhu NK; Cheedarla N; Bollimpelli VS; Gangadhara S; Edara VV; Lai L; Sahoo A; Shiferaw A; Styles TM; Floyd K; Fischinger S; Atyeo C; Shin SA; Gumber S; Kirejczyk S; Dinnon KH; Shi PY; Menachery VD; Tomai M; Fox CB; Alter G; Vanderford TH; Gralinski L; Suthar MS; Amara RR
    Nat Commun; 2021 Jun; 12(1):3587. PubMed ID: 34117252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
    He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
    Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
    Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
    Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization.
    Gu M; Torres JL; Li Y; Van Ry A; Greenhouse J; Wallace S; Chiang CI; Pessaint L; Jackson AM; Porto M; Kar S; Li Y; Ward AB; Wang Y
    Emerg Microbes Infect; 2021 Dec; 10(1):2016-2029. PubMed ID: 34651563
    [No Abstract]   [Full Text] [Related]  

  • 29. Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection.
    Li M; Guo J; Lu S; Zhou R; Shi H; Shi X; Cheng L; Liang Q; Liu H; Wang P; Wang N; Wang Y; Fu L; Xing M; Wang R; Ju B; Liu L; Lau SY; Jia W; Tong X; Yuan L; Guo Y; Qi H; Zhang Q; Huang Z; Chen H; Zhang Z; Chen Z; Peng X; Zhou D; Zhang L
    Front Immunol; 2021; 12():697074. PubMed ID: 34262569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2.
    Sun YS; Zhou JJ; Zhu HP; Xu F; Zhao WB; Lu HJ; Wang Z; Chen SQ; Yao PP; Jiang JM; Zhou Z
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of nanoparticle vaccines utilizing designed Fc-binding homo-oligomers and RBD-Fc of SARS-CoV-2.
    Liang Y; Xiao W; Peng Y; Zhang S; Dong J; Zhao J; Wang Y; Zhang M; Liu Z; Yu B
    Antiviral Res; 2024 Jul; 227():105917. PubMed ID: 38782067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
    Tostanoski LH; Gralinski LE; Martinez DR; Schaefer A; Mahrokhian SH; Li Z; Nampanya F; Wan H; Yu J; Chang A; Liu J; McMahan K; Ventura JD; Dinnon KH; Leist SR; Baric RS; Barouch DH
    J Virol; 2021 Nov; 95(23):e0097421. PubMed ID: 34523968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates.
    He L; Lin X; Wang Y; Abraham C; Sou C; Ngo T; Zhang Y; Wilson IA; Zhu J
    Sci Adv; 2021 Mar; 7(12):. PubMed ID: 33741598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity.
    Fougeroux C; Goksøyr L; Idorn M; Soroka V; Myeni SK; Dagil R; Janitzek CM; Søgaard M; Aves KL; Horsted EW; Erdoğan SM; Gustavsson T; Dorosz J; Clemmensen S; Fredsgaard L; Thrane S; Vidal-Calvo EE; Khalifé P; Hulen TM; Choudhary S; Theisen M; Singh SK; Garcia-Senosiain A; Van Oosten L; Pijlman G; Hierzberger B; Domeyer T; Nalewajek BW; Strøbæk A; Skrzypczak M; Andersson LF; Buus S; Buus AS; Christensen JP; Dalebout TJ; Iversen K; Harritshøj LH; Mordmüller B; Ullum H; Reinert LS; de Jongh WA; Kikkert M; Paludan SR; Theander TG; Nielsen MA; Salanti A; Sander AF
    Nat Commun; 2021 Jan; 12(1):324. PubMed ID: 33436573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of Glycan-masked SARS-CoV-2 RBD vaccines against SARS-related coronaviruses.
    Liang Z; Li C; Gong X; Ye G; Jiang Y; Shi H; Hussain A; Zhao M; Li M; Tian Y; Zhao W; Yang Y; Huang Y; Shen C; Yang M
    PLoS Pathog; 2024 Sep; 20(9):e1012599. PubMed ID: 39325829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.
    Wang Y; Wang L; Cao H; Liu C
    J Med Virol; 2021 Feb; 93(2):892-898. PubMed ID: 32691875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates.
    He Q; Mao Q; Peng X; He Z; Lu S; Zhang J; Gao F; Bian L; An C; Yu W; Yang F; Zhou Y; Yang Y; Li Y; Yuan Y; Yan X; Yang J; Wu X; Huang W; Li C; Wang J; Liang Z; Xu M
    Signal Transduct Target Ther; 2022 Mar; 7(1):69. PubMed ID: 35241645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike.
    Lu M; Dravid P; Zhang Y; Trivedi S; Li A; Harder O; Kc M; Chaiwatpongsakorn S; Zani A; Kenney A; Zeng C; Cai C; Ye C; Liang X; Shimamura M; Liu SL; Mejias A; Ramilo O; Boyaka PN; Qiu J; Martinez-Sobrido L; Yount JS; Peeples ME; Kapoor A; Niewiesk S; Li J
    Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33688034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice.
    Salzer R; Clark JJ; Vaysburd M; Chang VT; Albecka A; Kiss L; Sharma P; Gonzalez Llamazares A; Kipar A; Hiscox JA; Owen A; Aricescu AR; Stewart JP; James LC; Löwe J
    FEBS Lett; 2021 Sep; 595(18):2323-2340. PubMed ID: 34331769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
    Huang Q; Ji K; Tian S; Wang F; Huang B; Tong Z; Tan S; Hao J; Wang Q; Tan W; Gao GF; Yan J
    Nat Commun; 2021 Feb; 12(1):776. PubMed ID: 33536425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.